© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
February 12, 2021
The investigational tubulin inhibitor was also safe and well tolerated at continuous daily dosing.
October 01, 2020
Dual immune checkpoint blockade with the PD-1 inhibitor tislelizumab and the PD-L1 inhibitor BGB-A333 showed clinical activity in bladder cancer.
September 29, 2020
The results may help guide treatment selection with immunotherapy versus targeted agents in patients with kidney cancer.